8-K: Beyond Air Reports Record Revenue, Awaits FDA Decision

Beyond Air announced record quarterly revenue of $2.3 million, a 28% year-over-year increase, while awaiting FDA review for its second-generation LungFit PH system.

Summary

• Beyond Air reported its highest-ever quarterly revenue of $2.3 million for the quarter ended September 30, 2026, marking a 28% increase year-over-year and a 31% increase sequentially.
• The company is awaiting FDA approval for its second-generation LungFit PH system, which is designed with transport capability.
• Revenue guidance for calendar year 2026 is reaffirmed at $8 million (excluding the second-generation system), and for calendar year 2027 at $16-$18 million (including the second-generation system, pending approval).
• Research and development expenses decreased to $1.6 million from $2.5 million in the prior year period, primarily due to reduced costs for the second-generation LungFit PH.
• Selling, general, and administrative expenses were $4.6 million, down from $4.9 million in the prior year, mainly due to lower stock-based compensation.
• Net loss attributable to common stockholders was $7.8 million, or $3.76 per share, compared to a net loss of $7.9 million, or $24.98 per share, in the prior year period.
• The company reported $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by record revenue and strong year-over-year growth, though tempered by ongoing net losses and the pending FDA approval for the next-generation product.

Positives

• Achieved record quarterly revenue of $2.3 million, a 28% year-over-year increase.
• Demonstrated strong sequential revenue growth of 31% compared to the previous quarter.
• Reaffirmed full-year 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million.
• Reduced R&D expenses by $0.9 million year-over-year, indicating progress on the second-generation LungFit PH development.
• Slight decrease in SG&A expenses year-over-year.
• Received FDA Breakthrough Device Designation for LungFit GO for NTM-PD treatment.
• Announced definitive agreement for the sale of controlling interest in NeuroNOS Israel Ltd.

Negatives

• Reported a net loss of $7.8 million for the quarter.
• The second-generation LungFit PH system's commercial launch is contingent on FDA approval, which is still pending.
• Other expense increased significantly to $2.2 million from $0.6 million, largely due to increased debt and interest expense, and a charge for scrapped materials.
• The company has a history of losses and a substantial doubt about its ability to continue as a going concern.
• Cash, cash equivalents, restricted cash, and marketable securities decreased to $18.5 million from $24.7 million in the prior fiscal year-end.

Risks

• The second-generation LungFit PH system's PMA supplement remains under FDA review, with potential delays in approval and commercial launch.
• The company's ability to achieve its revenue guidance is subject to assumptions regarding demand, hospital adoption, pricing, and timely FDA approval.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may require additional financing to fund its operations and meet debt obligations, which could lead to dilution.
• The proposed NeuroNOS transaction may not close or realize its anticipated benefits.
• The company is deferring resources for LungFit GO development until the second-generation LungFit PH launch is established.
• Reliance on third-party contract manufacturers.
• Market acceptance of products and competition in the nitric oxide market.

Future Outlook

The company reaffirms its revenue guidance of $8 million for calendar year 2026 (excluding the second-generation LungFit PH system) and $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval. The commercial launch of the second-generation LungFit PH system is expected following FDA approval, with transport capability being a key feature.

Management Comments

• "Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval."
• "Our US pipeline is now experiencing unprecedented expansion with an acceleration in demand for our first-generation system and high receptivity to our technology and its operational efficiencies, creating a natural demand for our next generation product."
• "We are especially pleased with the pace of new account wins and rate of renewals, which speak to the high level of customer satisfaction with our unique technology all of which we believe we can leverage into the potential future launch of our second-generation LungFit PH system."
• "We remain encouraged by our active and productive discussions with the FDA and the progress we are making toward completing the remaining steps in the review process for the second-generation LungFit PH system."

Industry Context

StockSavvy.ai notes that Beyond Air's focus on nitric oxide delivery systems aligns with a growing interest in innovative respiratory therapies. The company's progress with its LungFit PH system, particularly the potential for transport capability in its second-generation device, could position it to capture a larger share of the hospital and home-care markets for NO therapy.

Related Party Transactions

• The company announced a definitive agreement for UNIVO Pharmaceutical Industries Ltd. to acquire its controlling interest in NeuroNOS Israel Ltd.

Stakeholder Impact

• Shareholders: Potential for increased value if the second-generation LungFit PH system receives FDA approval and drives revenue growth, but also risk associated with ongoing losses and potential need for future financing.
• Hospitals and Health Systems: Potential for improved patient care and operational efficiency with the second-generation LungFit PH system, especially with transport capability.
• Employees: Continued focus on commercialization and product development may lead to growth opportunities, but also uncertainty related to financial performance.

Next Steps

• Complete audit-readiness process in mid-December.
• Undergo FDA inspections and await final approval for the second-generation LungFit PH system.
• Advance preparations for the potential U.S. commercial launch of the second-generation LungFit PH system.
• Evaluate potential development partnerships for Beyond Cancer's pipeline.
• Transition fiscal year end to December 31, effective December 31, 2026, and file a transition report on Form 10-K/T.

Key Dates

Recommendation

The company shows positive revenue momentum and product development progress, but the significant net loss, ongoing reliance on future FDA approvals, and the substantial doubt about its ability to continue as a going concern warrant a cautious 'hold' rating. Investors should monitor the FDA decision on the second-generation LungFit PH system and the company's cash burn rate.

Keywords

LungFit PH, nitric oxide, medical device, FDA approval, revenue growth, financial results, PMA supplement, commercialization